Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants
(La Jolla Institute for Immunology) Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: Allergy & Immunology | COVID-19 | Infectious Diseases | Pfizer | SARS | Vaccines